TBPH Logo

Theravance Biopharma, Inc. (TBPH) 

NASDAQ
Market Cap
$474.04M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
16 of 774
Rank in Industry
14 of 432

Largest Insider Buys in Sector

TBPH Stock Price History Chart

TBPH Stock Performance

About Theravance Biopharma, Inc.

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as …

Insider Activity of Theravance Biopharma, Inc.

Over the last 12 months, insiders at Theravance Biopharma, Inc. have bought $20.92M and sold $97,102 worth of Theravance Biopharma, Inc. stock.

On average, over the past 5 years, insiders at Theravance Biopharma, Inc. have bought $20.92M and sold $717,283 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Samaha Eli (10 percent owner) — $62.75M.

The last purchase of 999,800 shares for transaction amount of $7.8M was made by Samaha Eli (10 percent owner) on 2024‑08‑07.

List of Insider Buy and Sell Transactions, Theravance Biopharma, Inc.

2024-11-11SaleSVP, COMM & MEDICAL AFFAIRS
4,000
0.0081%
$9.00$36,000+5.73%
2024-08-07Purchase10 percent owner
999,800
2.0479%
$7.80$7.8M+4.85%
2024-07-10SaleSVP, COMM & MEDICAL AFFAIRS
4,000
0.0088%
$9.00$36,0000.00%
2024-05-01Purchase10 percent owner
1.5M
3.0808%
$8.75$13.12M-3.51%
2024-02-22SaleSVP, COMM & MEDICAL AFFAIRS
1,254
0.0025%
$8.71$10,922+0.81%
2023-11-21SaleSVP, COMM & MEDICAL AFFAIRS
1,378
0.0026%
$10.29$14,180-12.97%
2023-11-14SaleSVP, RESEARCH & DEVELOPMENT
2,482
0.0047%
$10.22$25,366-12.66%
2023-10-16SaleSVP, RESEARCH & DEVELOPMENT
2,482
0.0047%
$9.03$22,412+0.83%
2023-09-14SaleSVP, RESEARCH & DEVELOPMENT
2,482
0.0048%
$9.89$24,547-5.72%
2023-08-22SaleSVP, COMM & MEDICAL AFFAIRS
1,807
0.0034%
$9.47$17,112-1.27%
2023-08-11SaleSVP, RESEARCH & DEVELOPMENT
2,322
0.004%
$9.99$23,197-5.77%
2023-07-14SaleSVP, RESEARCH & DEVELOPMENT
2,322
0.0037%
$9.84$22,848-3.47%
2023-06-14SaleSVP, RESEARCH & DEVELOPMENT
2,322
0.0038%
$10.69$24,822-8.55%
2023-06-08SaleSVP, COMM & MEDICAL AFFAIRS
1,790
0.0028%
$11.13$19,923-14.26%
2023-05-15SaleSVP, RESEARCH & DEVELOPMENT
2,322
0.0037%
$11.26$26,146-14.03%
2023-04-14SaleSVP, RESEARCH & DEVELOPMENT
2,323
0.0037%
$11.88$27,597-17.70%
2023-03-14SaleSVP, RESEARCH & DEVELOPMENT
2,323
0.0036%
$10.32$23,973-5.09%
2023-03-09SaleSVP, COMM & MEDICAL AFFAIRS
4,000
0.0063%
$10.20$40,800-1.51%
2023-03-06SaleSVP, RESEARCH & DEVELOPMENT
2,323
0.0037%
$10.05$23,346-0.15%
2022-12-14SaleCHIEF EXECUTIVE OFFICER
50,000
0.0741%
$11.19$559,500-7.40%

Insider Historical Profitability

26.45%
Samaha Eli10 percent owner
9511150
19.3417%
$9.6420
Winningham Rick ECHIEF EXECUTIVE OFFICER
1350797
2.747%
$9.6431+34.06%
PASQUALONE FRANKSVP, Chief Comm Ops Officer
213180
0.4335%
$9.6410+3.17%
GALA RENEE DSVP, Chief Financial Officer
171049
0.3478%
$9.6423+44.26%
MALKIEL BURTON Gdirector
56757
0.1154%
$9.6430+20.14%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Weiss Asset Management LP$66.89M15.337.46M0%+$03.41
Madison Avenue Partners, LP$62.9M14.427.01M0%+$010.3
Baupost Group$59.15M13.566.59M-11.12%-$7.4M1.67
BlackRock$37.75M8.654.21M-8.27%-$3.4M<0.01
Irenic Capital Management Lp$24.77M5.682.76M0%+$07.1
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.